Hillsdale Investment Management’s NovoCure NVCR Stock Holding History

Hillsdale Investment Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.33M	Sell	121,800 -10,000	-8%	-$125K	0.04%	333
2025 Q4	$1.7M	Hold	131,800	–	–	0.05%	330
2025 Q3	$1.7M	Sell	131,800 -8,100	-6%	-$108K	0.05%	320
2025 Q2	$2.49M	Buy	139,900 +3,000	+2%	+$52.3K	0.09%	258
2025 Q1	$2.44M	Buy	+136,900	New	+$3.11M	0.12%	197
2020 Q3	–	Sell	-10,300	Closed	-$611K	–	630
2020 Q2	$611K	Hold	10,300	–	–	0.06%	287
2020 Q1	$694K	Hold	10,300	–	–	0.08%	214
2019 Q4	$868K	Buy	+10,300	New	+$831K	0.08%	227

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Hillsdale Investment Management's NVCR Position: Q1 2026 in Review

Hillsdale Investment Management reduced its NovoCure (NVCR) stake by 7.6% in Q1 2026, selling an estimated $125K and leaving 121,800 shares worth $1.33M. The position accounts for 0.04% of the portfolio, ranked #333.

Hillsdale Investment Management first reported a position in NVCR in Q4 2019 and has held it in 8 quarters since. The position peaked at $2.49M in Q2 2025. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

Hillsdale Investment Management held 121,800 shares of NovoCure worth $1.33M as of Q1 2026.
Hillsdale Investment Management sold 10,000 NovoCure shares in Q1 2026, an estimated $125K.
NovoCure made up 0.04% of Hillsdale Investment Management's portfolio in Q1 2026, its #333 holding.
Hillsdale Investment Management first reported a position in NovoCure in Q4 2019 and has held it in 8 quarters since.
Hillsdale Investment Management's NovoCure position peaked at $2.49M in Q2 2025.
223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Hillsdale Investment Management's 13F filing for Q1 2026, filed 4 May 2026.